Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

• Main Authors: Mattia Bonsignori, Justin Pollara, Anthony A. Moody, Xi Chen, Kwan Ki Hwang, Thaddeus C. Gurley, Daniel M. Kozink, Dawn J. Marshall, John F. Whitesides, Chun Yen Tsao, Georgia D. Tomaras, David C. Montefiori, Guido Ferrari, Hua Xin Liao, Barton F. Haynes, Michael D. Alpert, David T. Evans, Peter B. Gilbert, Ying Huang, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Jerome H. Kim, Nelson L. Michael, George K. Lewis, Anthony DeVico
• Other Authors: Duke University School of Medicine
• Format: Article
• Published: 2018
• Subjects: Immunology and Microbiology
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/14248
• Institution: Mahidol University

The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the combination of low plasma anti-HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversely correlate with infec...